Foundation Medicine's Lynparza companion test clears FDA

By staff writers

July 2, 2019 -- The FoundationOne CDx genomic profiling tumor test is now cleared by the U.S. Food and Drug Administration (FDA) for guiding the use of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) in the first-line treatment of ovarian cancer.

The test helps identify patients with germline and somatic BRCA1 and BRCA2 mutations, who tend to respond better to treatment with PARP inhibitors. Lynparza (AstraZeneca/Merck) was approved by the FDA in December 2018 for use as a first-line maintenance treatment in BRCA-mutated patients as a means of extending the benefit of platinum-based chemotherapy, having previously been cleared for use more broadly in later stages of disease.

BRCA mutations are also associated with response in other solid tumor types targeted with PARP treatment, including breast cancer and prostate cancer.

The company noted that its test analyzes all genes in solid tumors that are cited in professional guidelines and that it may be used with 18 FDA-approved targeted therapies.

Why BRCA1/2 genetic testing rates are so low and how to fix them
Too few people with cancer are getting genetic testing for germline BRCA1 and 2 mutations in many countries, according to a study published on May 24...
Tumor mutational burden biomarker may not pass muster (again) at ASCO
Foundation Medicine is set to present data supporting its cancer diagnostics and the tumor mutational burden biomarker at the American Society of Clinical...
So far, so good with NCI pediatric molecular screening study
In a large molecular screening study sponsored by the U.S. National Cancer Institute (NCI), 24% of pediatric cancer patients were matched with targeted...
Next-generation sequencing offers hope for kids with cancer
Whole exome and RNA sequencing are useful tools for analyzing the molecular profiles of cancers in children and adolescents with a poor prognosis and...

Copyright © 2019

Last Updated np 8/2/2019 5:47:28 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.